Genomic Analyses of Acute Flaccid Myelitis Cases among a Cluster in Arizona Provide Further Evidence of Enterovirus D68 Role

Jolene R. Bowers, Michael Valentine, Veronica Harrison, Viacheslav Y. Fofanov, John Gillece, Josie Delisle, Bethany Patton, James Schupp, Krystal Sheridan, Darrin Lemmer, Scott Ostdiek, Harlori K. Bains, Jennifer Heim, Tammy Sylvester, Siru Prasai, Melissa Kretschmer, Nicole Fowle, Kenneth Komatsu, Shane Brady, Susan Robinson, Kathryn Fitzpatrick, Elizabeth Hutchins, Kendall Jensen, Paul Keim, David M. Engelthaler

ABSTRACT  Enteroviruses are a common cause of respiratory and gastrointestinal illness, and multiple subtypes, including poliovirus, can cause neurologic disease. In recent years, enterovirus D68 (EV-D68) has been associated with serious neurologic illnesses, including acute flaccid myelitis (AFM), frequently preceded by respiratory disease. A cluster of 11 suspect cases of pediatric AFM was identified in September 2016 in Phoenix, AZ. To determine if these cases were associated with EV-D68, we performed multiple genomic analyses of nasopharyngeal (NP) swabs and cerebrospinal fluid (CSF) material from the patients, including real-time PCR and amplicon sequencing targeting the EV-D68 VP1 gene and unbiased microbiome and metagenomic sequencing. Four of the 11 patients were classified as confirmed cases of AFM, and an additional case was classified as probable AFM. Real-time PCR and amplicon sequencing detected EV-D68 virus RNA in the three AFM patients from which NP swabs were collected, as well as in a fourth patient diagnosed with acute disseminated encephalomyelitis, a disease that commonly follows bacterial or viral infections, including enterovirus. No other obvious etiological causes for AFM were identified by 16S or RNA and DNA metagenomic sequencing in these cases, strengthening the likelihood that EV-D68 is an etiological factor. Herpes simplex viral DNA was detected in the CSF of the fourth case of AFM and in one additional suspect case from the cluster. Multiple genomic techniques, such as those described here, can be used to diagnose patients with suspected EV-D68 respiratory illness, to aid in AFM diagnosis, and for future EV-D68 surveillance and epidemiology.

IMPORTANCE  Enteroviruses frequently result in respiratory and gastrointestinal illness; however, multiple subtypes, including poliovirus, can cause severe neurologic disease. Recent biennial increases (i.e., 2014, 2016, and 2018) in cases of non-polio acute flaccid paralysis have led to speculations that other enteroviruses, specifically enterovirus D68 (EV-D68), are emerging to fill the niche that was left from poliovirus eradication. A cluster of 11 suspect cases of pediatric acute flaccid myelitis (AFM) was identified in 2016 in Phoenix, AZ. Multiple genomic analyses identified the presence of EV-D68 in the majority of clinical AFM cases. Beyond limited detection of
herpesvirus, no other likely etiologies were found in the cluster. These findings strengthen the likelihood that EV-D68 is a cause of AFM and show that the rapid molecular assays developed for this study are useful for investigations of AFM and EV-D68.

**KEYWORDS** AFM, EV-D68, acute flaccid myelitis, enterovirus, genomics, metagenomics

Enteroviruses comprise a broad assortment of viruses, causing a diverse array of disease manifestations involving respiratory, skin, neurologic, and gastrointestinal sites, but infections are also frequently asymptomatic (1). Before poliovirus (enterovirus C) vaccine implementation, upwards of 600,000 children worldwide were paralyzed each year by poliovirus (2). The recent increase in cases of non-polio acute flaccid paralysis (AFP) has led to speculations that other enteroviruses are emerging to fill the niche vacated via eradication of poliovirus (3, 4). Previously, enterovirus A71 (EV-A71) and several enterovirus B serotypes, mainly echoviruses and coxsackieviruses, were implicated in hundreds of cases of AFP following the success of global polio vaccine campaigns (3).

Enterovirus D68 (EV-D68), first characterized in 1962, did not emerge as a major cause of respiratory infections until 2009 (5). Shortly thereafter, EV-D68 was correlated with clusters of an AFP termed acute flaccid myelitis (AFM), which presents with demonstrable lesions in the spinal cord or brain stem, distinguishing it from other forms of AFP (6). In 2014, EV-D68 was detected in many AFM patients (7–15) and AFM cases temporally corresponded to peaks in EV-D68 infections (11, 16), although the upsurge in EV-D68 was orders of magnitude larger than the increase in AFM.

In 2016, 149 people in 39 U.S. states were classified as confirmed cases of AFM (17), correlating to regional outbreaks that were part of another nationwide seasonal increase in EV-D68 infection (15, 18, 19): this is likely a low estimate, and the number could rise if additional suspect cases from 2016 are reviewed (20). Late in the summer of 2016, physicians in Phoenix, AZ, noted a cluster of children with symptoms consistent with AFM (20). We employed highly sensitive analyses on clinical samples from that outbreak to identify possible etiologic agents, including targeted PCR and amplicon sequencing for EV-D68 and 16S microbiomic analysis and metagenomic analyses for other potential causes of AFM or other neurologic disease.

**RESULTS**

**Clinical results.** Table 1 includes clinical information for the 11 suspect pediatric AFM cases. Four of the eleven children met the case definition of confirmed AFM after medical record reviews and in-person interviews. One child met the case definition of probable AFM after medical record review showed pleocytosis without an alternative diagnosis despite a normal magnetic resonance imaging (MRI). Three of these five children had asthma, and another had a family history of asthma (20). The other children’s diagnoses recorded here were the leading differential diagnoses at the time data were abstracted and included acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS), Guillain-Barré syndrome (GBS), and neuromyelitis optica (NMO) (Table 1). Patient 4, diagnosed with confirmed AFM, was positive for coxsackievirus A10 in a stool sample collected 28 days post-onset of focal limb weakness. Genomic analyses were blinded from these results to prevent testing and analysis bias.

**EV-D68 real-time PCR and targeted amplicon sequencing.** From the 11 suspect AFM patients, six had nasopharyngeal (NP) swabs available for genomic analysis. Four of these six tested positive for EV-D68 by both real-time PCR and amplicon sequencing (Table 2). Three of these were from patients subsequently classified as confirmed cases of AFM, and one was from a patient with differential diagnoses of ADEM or MS. No NP swab was available from patient 4, who was the fourth confirmed AFM patient and was stool positive for coxsackievirus A10 by the clinical laboratory. None of the CSF specimens tested positive for EV-D68, despite the fact that two AFM patients had CSF
drawn 1 day following onset of their focal limb weakness (Table 2). Like patient 4 (confirmed AFM), no NP swab from the single probable AFM case (patient 5) was available for genomic analysis.

Though this sample set is too small to draw statistical conclusions from the data, sensitivity, specificity, and overall agreement of the PCR-based results on NP swabs when available, and on CSF otherwise, with the clinical diagnoses as the reference

TABLE 1 Patient clinical symptoms and initial testing resultsa

| Patient no. | Age (yr) | Case classification or leading differential diagnosis | Preceding illness | No. of days of illness to limb weakness onset | CSF white blood cells/mm³ | No. of limbs affected | MRI result(s) |
|-------------|---------|------------------------------------------------------|------------------|---------------------------------------------|---------------------------|---------------------|--------------|
| 1           | 3.5     | Confirmed AFM                                        | Respiratory, fever| 2                                           | 50                        | 1                   | LUE          |
| 2           | 10      | Confirmed AFM                                        | Respiratory      | 5                                           | 150                       | 4                   | T2 signal abnormality with anterior and posterior involvement, contiguous through multiple levels of the cord |
| 3           | 4       | Confirmed AFM                                        | Respiratory, fever| 2                                           | 207                       | 3                   | BUE, RLE    |
| 4           | 9       | Confirmed AFM                                        | GI, fever        | 2                                           | 115                       | 4                   | T2 signal abnormality in the anterior horn of the central gray cord |
| 5           | 12      | Probable AFM                                          | Respiratory      | 10                                          | 7                         | 1                   | LUE          |
| 6           | 12      | Unknown                                              | None             | 5                                           | 5                         | 2                   | BLE          |
| 7           | 7.5     | ADEM                                                 | Respiratory, fever| 0                                           | 7                         | 1                   | RUE          |
| 8           | 17      | NMO                                                  | Respiratory      | 10                                          | 22                        | 2                   | BLE          |
| 9           | 6.5     | GBS                                                  | None             | 5                                           | 1                         | 2                   | BLE          |
| 10          | 14      | MS/ADEM                                              | GI               | 6                                           | 5                         | 2                   | BLE          |
| 11          | 1.5     | Unknown                                              | GI, fever        | 0                                           | 0                         | 2                   | T4-T7 gray/white matter affected; edema of conus |

Diagnoses reflect whether the AFM case definition was met (confirmed AFM or probable AFM) or not, in which case the leading differential diagnosis at the time of data abstraction was recorded. MRI results for the patients who met the AFM case definitions are those described by the CDC neurology subject matter expert, while MRI results for patients who did not meet the AFM case definitions are those described by the attending radiologist. Other specimen testing included PCR for herpes simplex virus, West Nile virus, human herpesvirus 6, Epstein Barr virus, and Mycoplasma pneumoniae, as well as serology for West Nile virus and the VDRL test for syphilis (20). AFM, acute flaccid myelitis; ADEM, acute disseminated encephalomyelitis; NMO, neuromyelitis optica; GBS, Guillain-Barré syndrome; MS, multiple sclerosis; LUE, left upper extremity; BUE, bilateral upper extremity; RLE, right lower extremity; BLE, bilateral lower extremity; RUE, right upper extremity; NA, not applicable; GI, gastrointestinal.

TABLE 2 Study specimen information and molecular results of RNA analysis dataa

| Patient no. | Diagnosis | Specimen ID | Specimen type | No. of days of limb weakness to specimen collection | EV-D68 Tagman Cₚ | EV-D68 amplicon read count |
|-------------|-----------|-------------|---------------|-----------------------------------------------|------------------|--------------------------|
| 1           | AFM       | 48135       | CSF           | 2                                             | Neg              | 0                        |
| 2           | AFM       | 48136       | NP swab       | 4                                             | 32.1             | 8                        |
| 3           | AFM       | 48137       | NP swab       | 7                                             | 29.8             | 16                       |
| 4           | AFM       | 48143       | CSF           | 1                                             | Neg              | 0                        |
| 5           | AFM       | 48145       | NP swab       | 1                                             | Neg              | 0                        |
| 6           | Unknown   | 48124       | CSF           | 5                                             | Neg              | 0                        |
| 7           | ADEM      | 48134       | CSF           | 7                                             | Neg              | 0                        |
| 8           | NMO       | 48125       | CSF           | 5                                             | Neg              | 0                        |
| 9           | GBS       | 48131       | CSF           | 32                                            | Neg              | 0                        |
| 10          | MS/ADEM   | 48140       | CSF           | 9                                             | Neg              | 0                        |
| 11          | Unknown   | 48148       | CSF           | 15                                            | Neg              | 0                        |

The number of days from initial respiratory or gastrointestinal illness to specimen collection is the sum of the number of days of illness to limb weakness onset (Table 1) and the number of days of limb weakness to specimen collection. AFM, acute flaccid myelitis; ADEM, acute disseminated encephalomyelitis; NMO, neuromyelitis optica; GBS, Guillain-Barré syndrome; MS, multiple sclerosis; Cₚ, threshold cycle; Neg, negative. Probable.
standard, were calculated. With \( n = 10 \), considering one patient was without a clinical diagnosis, values with the Wilson score-based 95% confidence intervals (CIs) are as follows: sensitivity, 0.80 (95% CI, 0.38 to 0.96); specificity, 1.0 (95% CI, 0.57 to 1.0); and overall agreement, 0.90 (95% CI, 0.60 to 0.98). The 95% CIs of these measures show that the EV-D68 assay results are consistent with AFM diagnosis, as the lower bounds do not include 0.

Polymorphisms were identified among the amplicon sequences of each sample. Not including the primer regions, the VP1 gene sequence of sample 48136 was one single nucleotide polymorphism (SNP) different from a 2015 Japan isolate (GenBank accession no. LC203572) and several 2013 to 2014 Philippines isolates (accession no. AB992437, AB992417, KX789257, and KX789240). Sample 48137 was one SNP different from the five above (at a different locus) and from a 2016 Denmark isolate (accession no. KY457569). Samples 48139 and 48145 were a perfect match to many global strains from 2013 to 2017. Interpretation of these data is limited, however, as we only sequenced a fragment of the VP1 gene (Table 3), and sequencing error may have impacted consensus sequences due to low coverage in three of four samples (Table 2).

16S microbiomic analysis. The mean number of 16S sequence reads generated in the nine cerebrospinal fluid (CSF) samples analyzed for bacterial population was 1,612, with five samples having <200 reads indicating low bacterial loads (Fig. 1). Of the six NP swabs analyzed for bacterial population, two samples generated >4,000 reads, while the other four averaged 37,128 reads. The 16S PCR reagent blank (negative control) yielded 91 reads.

The bacterial composition of all NP swabs, considering all taxa at ≥1% of the total after the reagent blank taxa were removed, was characterized by normal upper respiratory flora, such as Corynebacterium, Bacillus, Propionibacterium, Streptococcus, Fusobacterium, Prevotella, Atopobium, Rothia, Veillonella, Leptotrichia, and Haemophilus (Fig. 1). Five of the six NP swabs contained a small number of unknown taxa. The variation in composition between patients appears analogous to the variation seen among healthy subjects (21, 22). Four of the six NP swabs were collected from patients with recent respiratory illness. However, the swabs were collected between 6 and 9 days after the onset of the respiratory illness. The other two patients (10 and 11) had gastrointestinal illness.

There was no evidence of CSF bacterial infection in any patients, as 16S read counts were low and no specimens were dominated by one organism, except sample 48148, characterized by Corynebacterium, a known CSF culture contaminant (23) and laboratory contaminant (24) (Fig. 1). The low read counts likely highlighted several contam-

### Table 3: Primers and probes used in this study

| Assay component | Name | Sequence |
|-----------------|------|----------|
| **Real-time PCR primer** | EVD68_F1 | CRGGGTCCTCCTGACTTRAC |
| | EVD68_F2 | ARGGGCCTCCTGACTGAC |
| | EVD68_F3 | YGGGCTCCTCCTGACTGAC |
| | EVD68_R1 | RCCTGAYTGCARTGGAAATG |
| | EVD68_R2 | GCTGAYTGCARTGGAAAYG |
| **Real-time PCR probe** | EVD68_FB1 | 6FAM-CARGCAATGTTTGTACCCTGACTGTC-BHQ |
| | EVD68_FB2 | 6FAM-CAAGCAATGTTTGTACRCCTGACTGTC-BHQ |
| **Amplicon sequencing primer** | EVD68_UT_F1 | ACCCAACTGATAGCAGCCRTGGCTCTGACTTRAC |
| | EVD68_UT_F2 | ACCCAACTGATAGCAGCCYGGCCTCTGACTGAC |
| | EVD68_UT_R1 | ACCCAACTGATAGCAGCCYGGCCTCTGACTGAC |
| | EVD68_UT_R2 | ACCCAACTGATAGCAGCCYGGCCTCTGACTGAC |
| **16S amplicon sequencing primer** | UT1-S-D-Bact-0341-b-S-17<sup>b</sup> | ACCCAACTGATAGCAGCCCTACGCGGNGGCWGCAG |
| | UT2-S-D-Bact-0785-a-A-21<sup>b</sup> | ACCCACTTGACTTTGCTCGACTACHVGGGATCTTTACTCC |

<sup>a</sup>The EV-D68 assays target the VP1 gene, and the real-time PCR results in a 94-bp amplicon. Underlined sequences are the universal tails. 6FAM, 6-carboxyfluorescein; BHQ, black hole quencher.

<sup>b</sup>Primers without these universal tails are from reference 70.
inants introduced during sample processing, as documented previously (24). Bacterial taxa found in the CSF specimens included Propionibacterium, Bacillus and Enterobacteriaceae, all known to be CSF culture contaminants (23, 25, 26) and laboratory contaminants (24). Although Enterobacteriaceae is a family containing well-known pathogens, the number of 16S reads matching these taxa was significantly lower than would be expected in an active CSF infection. Also found were Chryseobacterium, Delftia, Methylobacterium, Ralstonia, Roseomonas, Caulobacteriaceae, and Bradyrhizobiaceae, all known laboratory contaminants (24), but also recently shown to be part of the skin microbiome, as are Staphylococcus, Prevotella, and Sediminibacterium (27, 28), and thus, could be specimen collection contaminants. Some organisms were present in both the NP bacterial population and in the CSF data of a patient, such as Moryella, Fusobacterium, and Orhibacterium in patient 10, suggesting possible crossover of these organisms to the patient’s skin and contamination of the CSF specimen. Parvimonas, part of the normal oral flora, was found in one CSF sample, suggesting another possible transfer from the skin. Other organisms, generally not associated with clinical disease, were found in some CSF samples at higher proportion (Actinoplanes, Tepidimicrobium, Rhodospirillaceae, and Kastobacter), but total read counts were still relatively low for those samples (<200 reads); thus, their presence indicates contamination. Two CSF samples had reads from unknown taxa.

FIG 1 Results of microbiomic analysis by 16S rRNA partial gene sequencing after removing background taxa present in the 91 reads of a reagent-only negative-control sample, showing normal flora carriage in the NP swabs in all of the patients regardless of their neurologic disease diagnosis and probable contaminants in the CSF samples. The sample size is too small to detect differences in NP bacterial communities. 1, unknown.

| Patient | Diagnosis | Specimen |
|---------|-----------|----------|
| 1-11    | AFM       | ADEMI/MS |
| 2,669   | 48,136    | 48,137   |
| 31,051  | 48,145    | 48,132   |
| 35,733  | 48,139    | 48,147   |
| 3,868   | 48,138    | 48,135   |
| 47,633  | 48,143    | 48,143   |
| 34,097  | 3,871     | 1,489    |
| 1,489   | 816       | 7,831    |
| 3,871   | 42        | 160      |
| 42      | 69        | 158      |
| 816     | 174       | -        |

No. reads

2,669
31,051
35,733
3,868
47,633
34,097
3,871
1,489
816
7,831
160
69
158
174

unknown
No obvious or common etiology for neurologic disease or respiratory illness was found from the bacterial population analyses. There were no significant taxa from interpatient comparative analysis nor comparisons between EV-D68-positive and EV-D68-negative samples. Conclusive elimination of a bacterial role is limited, however, due to the small sample size and lack of healthy control data.

DNA and RNA metagenomic analyses. Total RNA libraries from 11 CSF and 6 NP samples and total DNA libraries from 2 CSF and 3 NP samples were sequenced (see Table S1 in the supplemental material). In both the CSF and NP swab RNA and DNA metagenomic data samples, human sequence reads were most common. Microorganism metagenomic results largely agreed with the 16S microbiomic analyses in organisms identified for the NP swabs and in identification of probable contamination in the CSF samples. From the metagenomic analyses, like the microbiomic analysis, no obvious bacterial etiology was found for the neurological illnesses in this outbreak.

Three different sequence analysis tools were employed to characterize the organism composition in each metagenomic sample for robustness and comprehensiveness. Most significantly, herpes simplex virus (HSV), a known neuroinvasive pathogen, was the top viral hit (from the MTS tool analysis) in two of the CSF DNA metagenomic samples from patients 4 and 8, samples 48136 and 48145 (Table S1). Patient 8 was diagnosed with NMO, and patient 4, an AFM patient, was noted to have a cold sore at the time of examination. Neither of these patients had NP swabs available for testing. Detailed methods and results from these tools can be found in the supplemental material (see Text S1).

Targeted query of metagenomic data. In addition to the metagenomic analysis pipelines, we performed a specific query for any reads matching EV-D68 in the metagenomic data with ASAP, utilizing bowtie2 (29) with no read clipping. EV-D68-specific reads were found in two samples, from patients 1 and 3, which were also EV-D68 positive by both real-time PCR and amplicon sequencing (Fig. 2). In sample 48136 (patient 1), one forward read and one reverse read (unpaired) aligned to the p3D RNA polymerase region. In sample 48145 (patient 3), a paired forward read and reverse read specifically matched EV-D68, aligning to p2A and p2B genes. BLAST analysis of these reads against the GenBank nucleotide database confirmed specificity of these reads to EV-D68.

DISCUSSION

Although EV-D68 has not been recognized as a definitive cause of AFM at this time (14), multiple lines of evidence of EV-D68-associated AFM have been reported: direct viral detection in patients (7–13, 16, 19, 30–32), a recent demonstration of Koch’s postulate in a mouse model with EV-D68 (33), fulfillment of most of the Bradford Hill causation criteria by two independent analyses (34, 35), and most recently, the estab-
lishment that multiple EV-D68 strains from the 2014 outbreaks are neurotropic (i.e., infect and replicate in human neuronal cells) (36). Epidemiologically, EV-D68 has been shown to have a biennial circulation pattern in Europe (37) and in the United States, with increased incidence in 2014, 2016, and seemingly in 2018 (38) recapitulating the patterns of increased AFM reports in the same years (17). The suspected AFM cluster in Phoenix, AZ, in 2016 provided a unique opportunity to genomically explore AFM patient samples for the presence of EV-D68.

Our PCR and sequencing results found that NP swabs from all three confirmed AFM patients for which swabs were available were positive for EV-D68, and metagenomic data contained EV-D68 sequence in two of the three, adding to the strength and consistency of evidence supporting an EV-D68 etiology of AFM (34, 35). No NP swabs were available from the fourth confirmed case or single “probable” case. Not all published AFM cases show evidence of EV-D68, suggesting possible additional causes. The confirmed AFM patient for whom no NP swab was available was previously identified to be stool positive for coxsackievirus (20), a possible cause for AFM (35). However, EV-D68 may be present and yet go undetected in many cases, and we illustrate that different methods and analyses result in variable detection of EV-D68. In this case cluster, the clear detection of EV-D68 by real-time PCR required a preamplification step. Metagenomic analyses were performed mainly for the purpose of identifying potential alternative etiologies and resulted in detection of a limited presence of EV-D68 reads, suggesting that viral RNA was present at very low levels, possibly due to actual low viral loads or RNA degradation. (Further discussion of the metagenomic results can be found in the supplemental material.)

Previous studies have determined that CSF is not a highly useful specimen type for EV-D68 detection (39). Despite detection from NP swabs, we did not detect EV-D68 in the CSF specimens from the AFM patients, an outcome that has been frequently reported (7, 11, 13, 40). EV-D68 has been documented in CSF in limited cases, including (i) a fast-progressing, fatal case of meningomyeloencephalitis (41), (ii) an undescribed case of acute flaccid paralysis in 2005 (42), (iii) a hematopoietic stem cell transplant recipient on mild immunosuppressants (43), (iv) a single patient in an Argentinian cluster (30), and (v) a CSF specimen contaminated with blood cells (limiting conclusions as to the nature of the viral infection) (14). Other neuropathic enteroviruses are also rarely detected in CSF (39, 44), including poliovirus (https://www.cdc.gov/polio/us/lab-testing/diagnostic.html; 45); therefore, testing recommendations for suspect viral neurologic illness typically include collection of stool and/or NP swabs (46, 47). EV-D68 viremia is an exceedingly rare finding; a recently developed EV-D68 mouse model suggests viral dissemination occurs via a direct neural pathway rather than via a hematogenous route (33), although Greninger et al. did report EV-D68 in the blood of one child diagnosed with AFM (7).

Several hypotheses have been suggested to explain the neurologic pathology, given the low incidence of direct neurologic infection with EV-D68. AFM has been proposed to be caused by an aberrant immune response in some patients, elicited by the enteroviral infection (7); virus-induced autoimmune damage is a well-documented etiology of neurologic disease (47). However, it has been noted that clinical and neuroradiographic findings are more consistent with EV-D68 neuroinvasion (11, 14), and as demonstrated in a mouse model, there was no beneficial effect of immunosuppression with steroids, while immunotherapy containing anti-EV-D68 antibodies was effective, countering the autoimmune hypothesis (48). Another proposed hypothesis is that differences in viral infection outcomes are likely due to complex combinations of viral genotype, interaction of virus with respiratory mucosa, its microbiome, host immunity (modulated partly by the microbiome), and/or environmental factors (49). Recent clusters of AFM have been associated with widespread strains in particular phylogenetic clades. Genomes from the 2012 to 2014 EV-D68 spike in the United States formed a new clade, B1, nested within clade B and characterized by particular mutations that were hypothesized to elevate virulence (7, 36, 50), while 2014 genomes from other countries formed a related clade, B3, also nested within clade B with unique
mutations (51). EV-D68 circulating in 2016 belonged to clade B3 (15, 18, 19), including isolates detected in sporadic cases of AFM (52). Hixon et al. used a mouse model to show four out of five 2014 EV-D68 isolates from clades A, B, and B1 caused paralysis using intracerebral injection, and a clade B1 isolate rarely caused paralysis using intranasal inoculation. Brown et al. recently demonstrated that strains from multiple clades displayed neuroinvasive capabilities in human neuronal cell lines (36). Greninger et al. documented EV-D68 infections in which one sibling suffered subsequent AFM, while the other did not (7). These observations suggest that neurologic outcomes are not necessarily strain driven. In another study, enteric viruses (e.g., poliovirus) in mice have been shown to exploit gut bacteria in order to facilitate host infection, and mice with depleted gut microbes were less susceptible (53). Disease severity of other viral infections (e.g., respiratory syncytial virus [RSV]) has been correlated with NP microbiome composition and host immune factors in children (54). However, our sample set did not include healthy controls and was too small to correlate microbiome structure with disease. Regardless of the factors involved, the likelihood that EV-D68 infection results in neurologic disease appears similar to that of other enteroviruses, such as poliovirus (4).

Our finding of the normally quiescent human endogenous retrovirus K (HERV-K) in the patient CSF samples (see the supplemental material) may add to the complexity of AFM and other neurologic manifestations. However, as our yield of RNA after DNase treatment and prior to RNA amplification was very low (data not shown), we suspect that residual DNA may be confounding these findings. Human genomic DNA harbors many HERV proviruses or remnants thereof (55); thus, we interpret our metagenomic hits to HERV-K with caution. Nevertheless, activation of HERVs by exogenous viruses (e.g., herpesviruses and HIV) is well documented (55, 56). Endogenous retroviruses have been shown to cause or exacerbate disease in some mammal species (55), and the HERV-K envelope protein is known to cause neuronal degeneration in vitro and in vivo (52). Additionally, antiretroviral therapy quelled HERV-K expression and amyotrophic lateral sclerosis (ALS)-like motor neuron disease in HIV patients (57). These observations ought to prompt further investigation in this area to potentially offer new insight into virus-induced neurologic disease. Notably, our observations also highlight one drawback to the removal of human data, which would include endogenous proviruses, from an RNA data set before analysis, as is common with metagenomic analysis tools.

The confirmed AFM patient (patient 4) who did not have evidence of EV-D68 (for which an NP swab was not available for analysis) did have HSV DNA in the CSF (sample 48127) by MTS bioinformatics analysis (see the supplemental material). The treating physician also noted the presence of a cold sore in this patient. The initial diagnostic screen for HSV in CSF was negative; however, false-negative HSV PCR results are often observed (47, 58). HSV is an established etiologic agent of other neurological diseases (47), is known to take a neural route of invasion of the central nervous system (CNS), and can reside at relatively high levels in the CSF of patients with HSV-caused encephalomyelitis (47). Discovery of HSV DNA in the metagenomic CSF data for this patient supports a possible HSV etiology in this case.

The single non-AFM EV-D68-positive sample (48139) was an NP swab from a patient whose differential diagnoses included ADEM or MS at the time of sample collection. Enteroviruses are a known cause of ADEM or MS at the time of sample collection. Enteroviruses are a known cause of ADEM (59–63), including type D68 specifically (60). Additionally, ADEM and MS have overlapping diagnostic criteria with AFM. Among the many diagnostic criteria, ADEM is characterized by lesions in the white and gray matter evident from magnetic resonance imaging (MRI), and the lesion patterns are variable (64).

For this study, we took several highly sensitive molecular-based approaches: first to check for the presence of EV-D68 in a cluster of children suffering neurologic symptoms with suspect AFM and second to assess samples for other possible etiological causes. In the former approach, though the sample set was small, our sensitivity, specificity, and overall agreement measures show that the EV-D68 assay results are consistent with AFM diagnosis; however, there is confounding between AFM diagnosis and availability of NP swabs. A discordance rate between AFM in NP and CSF samples would be
required to establish assay validation of EV-D68 and AFM diagnosis. In the latter approach, in addition to finding variability in detection of EV-D68 among the analysis methods (discussed above), we found variability among results generated by the 16S microbiomic and metagenomic analyses. The 16S sequence analysis was performed on DNA extracted from specimens, while most of the metagenomic data (save four samples) were generated from RNA extracted from specimens. Additionally, all of the metagenomic analyses we performed counted only species-specific sequence, with any reads that originated from any one of multiple species removed to prevent misleading results. The difference in the material recovered through each extraction method and the vast difference in the analysis of each approach likely explain much of the difference between results from 16S and metagenomic analyses. Among the metagenomic analyses, different databases and read filtering criteria were likely responsible for the relatively small differences in results for the same NP swab data sets. For the CSF samples, as the vast majority of data were host sequence, the relatively small amounts of contaminant microbial data were almost solely in the MTS results.

Identification of the etiology of AFM and related illnesses is important in order to understand risk factors, focus surveillance efforts, properly treat diagnosed AFM patients, and to help limit future outbreaks. Emphasis must be placed on the timely collection and appropriate handling of patient specimens in order to increase the likelihood of detection of RNA viruses—in this case EV-D68 (7, 9, 14, 30). The severity and outcome of AFM are devastating (3, 65), and delayed detection and improper management could worsen outcome (11). The use of multiple molecular and bioinformatic tools is still necessary until preferred sample types and definitive diagnostic markers are identified. Additionally, acknowledgment of EV-D68 as a likely etiologic agent of AFM could allow for improved surveillance and response and provide support for resource expenditure for vaccine development to eventually prevent AFM or other EV-D68 neurologic disease.

MATERIALS AND METHODS

Cluster identification and sample collection. In August and September 2016, 11 children presented to a Maricopa County (Phoenix), AZ, facility with focal limb weakness, all but one having immediate prior respiratory, febrile, and/or gastrointestinal illness. Initial differential diagnoses included transverse myelitis and AFM (20). As part of standard of care, cerebrospinal fluid (CSF) samples were collected from all patients between 1 and 32 days from onset of focal limb weakness, and nasopharyngeal (NP) swabs were collected from 6 of the 11 patients 1 to 14 days following onset of illness. Samples were submitted for testing and then stored at −20°C. Sample and testing information is included in Tables 1 and 2. The CSF and NP swab samples were deidentified and coded for subsequent genomic analyses, and institutional review board approval was not required, as the remnant samples were used for public health surveillance. Chart reviews and patient interviews were conducted during the course of sample analysis; therefore, all genomic analyses were blind. AFM was clinically diagnosed according to the 2015 CDC case definition, as described previously (20). The leading differential diagnosis at the time data were abstracted was recorded for the non-AFM case children (Table 1).

Nucleic acid extraction. DNA was extracted from 200 to 400 µl of each patient sample with the DNeasy blood and tissue kit (Qiagen) using the Gram-positive protocol in the supplied handbook with some modifications. Initial lysis was extended to 60 min at 37°C, and secondary lysis was performed with proteinase K at 56°C for 30 min. RNA was extracted from 100 to 400 µl of specimen with the High Pure viral RNA kit (Roche).

Real-time PCR and targeted amplicon sequencing. EV-D68 VP-1 sequences from 2014 to 2016 were collected from NCBI’s nucleotide database. Sequences were aligned in SeqMan (DNASTar) to identify conserved regions for primer design, and assays were designed with guidance from RealTimeDesign (Biosearch Technologies). Each primer and probe were run through BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to check for cross-reactivity to other relevant targets or species, including other enteroviruses and humans. The assay, listed in Table 3 and mapped in Fig. 2, results in a 94-bp amplicon. For amplicon sequencing, a universal tail sequence was added to each primer (Table 3) (20).

First-strand cDNA synthesis of the total RNA was performed with a high-capacity cDNA reverse transcription kit (Thermo Fisher Scientific). Preamplification, which has been shown to greatly increase sensitivity in complex samples (66, 67), was performed using the TaqMan PreAmp master mix (Thermo Fisher Scientific) with the EV-D68 primers (Table 3) at a final concentration of 5 to 10 nM. Real-time PCR was run on the 7900HT (Thermo Fisher Scientific) in 10-µl reaction mixtures containing 5 µl PerfeCTa FastMix II, 400 nM each forward primer, 600 nM each reverse primer, 200 nM each probe, and 4 µl preamplified template, with denaturation at 95°C for 3 min and 40 cycles of 95°C for 15 s and 60°C for 1 min.

Amplicon library preparation using universal tails was described previously (68). The initial gene-specific PCR comprised 12 µl 2× Kapa 2 G Fast Multiplex Mastermix (Kapa Biosystems), 10 µl primer mix...
yielding a final PCR concentration of 200 nM each, and 2 μL DNA template from each sample, and was
denatured at 98°C for 2 min, and then cycled 20 times at 95°C for 15 s, 60°C for 30 s, and 72°C for 1 min
30 s, with final extension at 72°C for 1 min. A second PCR using the universal tail-specific primers (Table 3)
added Illumina's sample-specific index and sequencing adapters. This PCR comprised 12.5 μL 2× Kapa
HiFi HotStart ReadyMix (Kapa Biosystems), universally tailed forward and reverse primers at 400 nM each,
and 10.5 μL cleaned gene-specific PCR product for a final volume of 25 μL and was denatured at 98°C for
2 min and then cycled 8 times for RNA metagenomic samples and 12 times for DNA at 98°C for 30 s, 65°C
for 20 s, and 72°C for 30 s, with final extension 72°C for 5 min. Final PCR products were cleaned with 1×
Agencourt AMPure XP beads (Beckman Coulter). Amplicon libraries from individual samples were
quantified by quantitative PCR (qPCR) using the Kapa library quantification kit (Kapa Biosystems)
and then pooled in equimolar concentration for sequencing on the Illumina MiSeq platform with the 2×
250-bp version 2 kit.

165 microbiome library preparation, sequencing, and analysis. Partial 16S rRNA genes in each
metagenomic sample were amplified by PCR and prepared for sequencing as described previously (69)
using the primer pair 5′-d-Bact-0341-b-S-17 and 5′-d-Bact-0785-a-A-21 (70) with universal tail sequences
(Table 3), resulting in an amplicon of 481 bp that spans the V3 and V4 regions. Amplification was
performed in a 25-μL reaction volume containing 12.5 μL Q5 Hot Start high-fidelity 2× master mix (New
England Biolabs, Inc.), 500 nM each primer, and 5 to 10 μL of DNA using thermal conditions previously
described (69). Amplicons were purified using the Agencourt AMPure XP beads (Beckman Coulter)
following the manufacturer’s protocol. To separate the bacterial 16S amplicon from the human mito-
chondrial amplicon (69), the samples were processed through the BluePippin DNA size selection system
(Sage Science). The index PCR comprised 12.5 μL of Kapa HiFi HotStart ReadyMix (Kapa Biosystems), 400
nM each indexing primer specific to each universal tail, and 10 μL of DNA in a final reaction volume of
25 μL run at 98°C for 2 min and then 10 cycles at 98°C for 30 s, 65°C for 20 s, and 72°C for 30 s, with a final
hold at 72°C for 5 min. Indexed libraries were purified, quantified, and pooled as described above, and
sequenced on the Illumina MiSeq platform with the 2× 300-bp version 3 kit.

Bacterial community content and diversity were examined with QIIME (71), using uclust (72) to pick
operational taxonomic units (OTUs), PyNAST (73) to align reads to the Greengenes 16S gene database
version 13_8 (74), ChimeraSlayer (75) to detect and filter chimera sequences, and the Greengenes
taxonomic classification system (76) to assign taxonomy. A DNA extraction blank and a 16S PCR reagent
blank were included in the sample preparation and analysis.

DNA and RNA metagenomic library preparation, sequencing, and analysis. Total RNA was
subjected to DNase I treatment and concentration using RNA Clean and Concentrator-3 (Zymo Research)
and then amplified using the SeqPlex RNA amplification kit (Sigma-Aldrich). Total DNA was subject to
fragmentation using a Q800R2 sonicator (QSonica). RNA and DNA metagenomic sequence libraries were
prepared for sequencing and quantified using the Kapa Hyper Prep kit and Kapa library quantification kit
(Kapa Biosystems). RNA and DNA libraries were sequenced on the Illumina HiSeq 2500 at 2× 100 bp
using v3 chemistry. To deposit nonidentifying data in NCBI’s SRA database, computational subtraction
of human sequence data was performed. For this, raw reads were aligned to a human genome (taxID 9606)
using bowtie (29) version 2.2.2 with default parameters, and SAMtools (77) version 1.4.1 was used to
take only paired reads where neither read mapped to the human genome. Finally, BEDTools (78)
version 2.62 was used to reconstitute the extracted reads into FASTQ format. These data were submitted
to the SRA database. By these methods, viral sequence data may be present in the human genome
reference sequence (e.g., herpesviruses and HERVs) are subtracted along with human sequence data.
Three metagenomic analysis tools, MTS (A. Perry, T. Schneider, and V. Fofanov, poster, presented on
21 June 2017 at the Qiime2 Workshop [https://workshops.qiime2.org/]) in Las Vegas, NV), GOTTCHA (79),
and MetaPhlAn (80), were employed for thorough taxonomic classification of reads from each sample;
the details of which can be found in the supplemental material. These three methods represent the
spectrum of potential databases that can be used for metagenomic data query, ranging from the most
inclusive (MTS, which uses the entire NCBI GenBank microbial database) to the most focused (MetaPhlAn,
which uses marker genes only). For all metagenomic analyses, background results from a blank were
subtracted from the sample data where appropriate.

EV-D68 amplicon and metagenomic data targeted analysis. Amplicon and metagenomic se-
quencing results were analyzed using the automated amplicon sequencing analysis pipeline ASAP, as
described in detail previously (68, 81, 82). Briefly, amplicon or metagenomic sequence reads were first
trimmed of adapter and read-through sequences with Trimmomatic (83) and then mapped to a reference
sequence with bowtie2 (29). Amplicon sequence was mapped to the PCR amplicon region of a 2016
EV-D68 VP1 gene (GenBank accession no. KY385890). Metagenomic data were mapped to the EV-D68
whole-genome sequence (accession no. KY385890). Table 84 was used to verify results.

Data availability. EV-D68 assay amplicon data have been deposited in NCBI’s SRA database under
BioProject no. PRJNA377726 (20). Amplicon read data and metagenomic data were deposited in NCBI’s
SRA under BioProject no. PRJNA474932. Viral sequence data will be made available upon request.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at https://doi.org/10.1128/mBio.02262-18.

TEXT S1, DOCX file, 0.1 MB.

TABLE S1, XLSX file, 0.1 MB.
ACKNOWLEDGMENTS

We gratefully acknowledge Rebecca Sunenshine and Sally Ann Iverson from the Maricopa County Department of Public Health for their steadfast leadership in this outbreak response and Bonnie LaFleur of the University of Arizona for technical assistance in data analysis.

This study was funded by contract 200-2016-92313 with the Centers for Disease Control and Prevention under their Advanced Molecular Detection Initiative. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

REFERENCES

1. Noor A, Krilov LR. 2016. Enterovirus infections. Pediatr Rev 37:505–515. https://doi.org/10.1542/pir.2016-0103.
2. Nathanson N, Kow OM. 2010. From eradication to reactivation: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 172:1213–1229. https://doi.org/10.1093/aje/kwq320.
3. Suresh S, Forgie S, Robinson J. 2018. Non-polio enterovirus detection with acute flaccid paralysis: a systematic review. J Med Virol 90:3–7. https://doi.org/10.1002/jmv.24933.
4. Wiznitzer M, Nath A. 2017. Acute flaccid myelitis and enterovirus D68: deja vu all over again. Neurology 89:112–113. https://doi.org/10.1212/WNL.0000000000004096.
5. Tokarz R, Firth C, Madhi SA, Howie SR, Wu W, Sall HA, Haq S, Briese T, Lipkin WI. 2012. Worldwide emergence of multiple clades of enterovirus 68. J Gen Virol 93:1952–1958. https://doi.org/10.1099/vir.0.043935-0.
6. Maloney JA, Mirsky DM, Messacar K, Dominguez SR, Schreiner T, Stence N. 2015. MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak. AJNR Am J Neuroradiol 36:245–250. https://doi.org/10.3174/ajnr.A4188.
7. Greninger AL, Naccache SN, Messacar K, Clayton A, Yu G, Somasekar S, Federman S, Stryke D, Anderson C, Yagi S, Messenger S, Wadford D, Xia D, Wang J, Van Haren K, Dominguez SR, Glaser C, Aldrovandi G, Chiu CY. 2015. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012–14): a retrospective cohort study. Lancet Infect Dis 15:671–682. https://doi.org/10.1016/S1473-3099(15)00993-9.
8. Messacar K, Schreiner TL, Maloney JA, Wallace A, Ludke J, Oberste MS, Nix WA, Robinson CC, Glade MP, Abzug MJ, Dominguez SR. 2015. A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet 385:1662–1671. https://doi.org/10.1016/S0140-6736(14)62457-0.
9. Aliabadi N, Messacar K, Pastula DM, Robinson CC, Leshem E, Sejvar JJ, Pastula DM, Feikin DR, Dominguez SR. 2016. Enterovirus D68 infection in children with acute flaccid myelitis, Colorado, USA, 2014. Emerg Infect Dis 22:1387–1394. https://doi.org/10.3201/eid2208.151949.
10. Ayscue P, Van Haren K, Haffner K, Wadford E, Wadford D, Xia D, Wang J, Van Haren K, Dominguez SR, Glaser C, Aldrovandi G, Chiu CY. 2015. Novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012–14): a retrospective cohort study. Lancet Infect Dis 15:671–682. https://doi.org/10.1016/S1473-3099(15)00993-9.
11. Ayscue P, Van Haren K, Haffner K, Wadford E, Wadford D, Xia D, Wang J, Van Haren K, Dominguez SR, Glaser C, Aldrovandi G, Chiu CY. 2015. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012–14): a retrospective cohort study. Lancet Infect Dis 15:671–682. https://doi.org/10.1016/S1473-3099(15)00993-9.
12. Aliabadi N, Messacar K, Pastula DM, Robinson CC, Leshem E, Sejvar JJ, Nix WA, Oberste MS, Feikin DR, Dominguez SR. 2016. Enterovirus D68 infection in children with acute flaccid myelitis, Colorado, USA, 2014. Emerg Infect Dis 22:1387–1394. https://doi.org/10.3201/eid2208.151949.
13. Tokarz R, Firth C, Madhi SA, Howie SR, Wu W, Sall HA, Haq S, Briese T, Lipkin WI. 2012. Worldwide emergence of multiple clades of enterovirus 68. J Gen Virol 93:1952–1958. https://doi.org/10.1099/vir.0.043935-0.
14. Maloney JA, Mirsky DM, Messacar K, Dominguez SR, Schreiner T, Stence N. 2015. MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak. AJNR Am J Neuroradiol 36:245–250. https://doi.org/10.3174/ajnr.A4188.
15. Greninger AL, Naccache SN, Messacar K, Clayton A, Yu G, Somasekar S, Federman S, Stryke D, Anderson C, Yagi S, Messenger S, Wadford D, Xia D, Wang J, Van Haren K, Dominguez SR, Glaser C, Aldrovandi G, Chiu CY. 2015. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012–14): a retrospective cohort study. Lancet Infect Dis 15:671–682. https://doi.org/10.1016/S1473-3099(15)00993-9.
16. Ayscue P, Van Haren K, Haffner K, Wadford E, Wadford D, Xia D, Wang J, Van Haren K, Dominguez SR, Glaser C, Aldrovandi G, Chiu CY. 2015. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012–14): a retrospective cohort study. Lancet Infect Dis 15:671–682. https://doi.org/10.1016/S1473-3099(15)00993-9.
17. Aliabadi N, Messacar K, Pastula DM, Robinson CC, Leshem E, Sejvar JJ, Pastula DM, Feikin DR, Dominguez SR. 2016. Enterovirus D68 infection in children with acute flaccid myelitis, Colorado, USA, 2014. Emerg Infect Dis 22:1387–1394. https://doi.org/10.3201/eid2208.151949.
18. Ayscue P, Van Haren K, Haffner K, Wadford E, Wadford D, Xia D, Wang J, Van Haren K, Dominguez SR, Glaser C, Aldrovandi G, Chiu CY. 2015. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012–14): a retrospective cohort study. Lancet Infect Dis 15:671–682. https://doi.org/10.1016/S1473-3099(15)00993-9.
19. Aliabadi N, Messacar K, Pastula DM, Robinson CC, Leshem E, Sejvar JJ, Pastula DM, Feikin DR, Dominguez SR. 2016. Enterovirus D68 infection in children with acute flaccid myelitis, Colorado, USA, 2014. Emerg Infect Dis 22:1387–1394. https://doi.org/10.3201/eid2208.151949.
30. Ruggieri V, Paz MI, Peretti MG, Rugilo C, Bologna R, Freire C, Vergel S, Kramer R, Sabatier M, Wirth T, Pichon M, Lina B, Schuffenecker I, Josset
31. Knoester M, Helfferich J, Poelman R, Van Leer-Buter C, Brouwer OF, Anonymous. 2016. Rapid risk assessment— enterovirus detections asso-
32. Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA, Centers for
33. Hixon AM, Yu G, Leser JS, Yagi S, Clarke P, Chiu CY, Tyler KL. 2017. A
34. Dyda A, Stelzer-Braid S, Adam D, Chughtai AA, MacIntyre CR. 2018. The
35. De Gascun CF. 2017. Seroepidemiological and phylogenetic character-
36. Brown DM, Hixon AM, Oldfield LM, Zhang Y, Novotny M, Wang W, Das
37. Kramer R, Sabatier J, Poelman R, Van Leer-Buter C, Brouwer OF, Niesters HGM, Tyler KL, Abzug MJ, Domínguez SR. 2018. Enterovirus D68 and acute flaccid myelitis—evaluating the evidence for causality. Lancet Infect Dis 18:
38. Suarez-Arrabal MC, Chaussabel D, Cohen DM, Sanders EA, Ramilo O, Bogaert D, Mejias A. 2016. Nasopharyngeal microbe, host transcriptome, and disease severity in children with respiratory syncytial virus infection. Am J Respir Crit Care Med 194:1104–1115. https://doi.org/10.1164/rcr.201602-0220OC.
39. Christensen T. 2016. Human endogenous retroviruses in neurologic disease. APSM 124:116–126. https://doi.org/10.1111/apm.12486.
40. Brown DM, Hixon AM, Oldfield LM, Zhang Y, Novotny M, Wang W, Das SR, Shabman RS, Tyler KL, Scheuermann RH. 2018. Contemporary circu-
41. Kramer R, Sabatier J, Mirth W, Tichon M, Bova R, Schuffenecker I, Josset L. 2018. Molecular diversity and biennial circulation of enterovirus D68: a systematic screening study in Lyon, France, 2010 to 2016. Euro Surveill 23:1700711. https://doi.org/10.28615/1966-7917.2018.23.17.00310.
42. New York State Department of Health. 2018. NYS Department of Health confirms case of enterovirus respiratory illness. http://www.health.ny.gov/press/releases/2018/2018-10-12_enterovirus_ev_d68.htm. Accessed 16 October 2018.
43. Guerra JA, Waters A, Kelly A, Morley U, O'Reilly P, O'Kelly E, Dean J, Cunney R, O’Lorcan P, Cotter S, Connell J, O’Gorman J, Hall WW, Carr M, De Gascun CF. 2017. Seroepidemiological and phylogenetic characterization of neurotropic enteroviruses in Ireland, 2005–2014. J Med Virol 89:1550–1558. https://doi.org/10.1002/jmv.24765.
44. Bonvitt J, Poel A, DeBolt C, Gonzales E, Lopez A, Routh J, Rietberg K, Bonwitt J, Poel A, DeBolt C, Gonzales E, Lopez A, Routh J, Rietberg K, Wali RK, Lee AH, Kam JC, Jonsson J, Thatcher A, Poretz D, Ambardar S, Archer LP, Donnelly R, Altizer S, Bowers et al.
64. Wender M. 2011. Acute disseminated encephalomyelitis (ADEM). J Neurolimmunol 231:92–99. https://doi.org/10.1016/j.jneuroim.2010.09.019.

65. Martin JA, Messacar K, Yang ML, Maloney JA, Lindwall J, Carry T, Kenyon P, Sillau SH, Olesek J, Tyler KL, Dominguez SR, Schreiner TL. 2017. Outcomes of Colorado children with acute flaccid myelitis at 1 year. Neurology 89: 129–137. https://doi.org/10.1212/WNL.0000000000004081.

66. Del Gaudio S, Cirillo A, Di Bernardo G, Galderisi U, Thanassoulas T, Pitsios T, Cipollaro M. 2013. Preamplification procedure for the analysis of ancient DNA samples. ScientificWorldJournal 2013:734676. https://doi.org/10.1155/2013/734676.

67. Del Gaudio S, Cirillo A, Di Bernardo G, Galderisi U, Cipollaro M. 2010. A preamplification approach to GMO detection in processed foods. Anal Bioanal Chem 396:2135–2142. https://doi.org/10.1007/s00216-009-3199-5.

68. Bowers JR, Lemmer D, Sah J, Pearson T, Driebe EM, Wojack B, Saubolle MA, Engelthaler DM, Keim P. 2016. KlebSeq, a diagnostic tool for surveillance, detection, and monitoring of Klebsiella pneumoniae. J Clin Microbiol 54:2582–2596. https://doi.org/10.1128/JCM.00927-16.

69. Lal D, Keim P, Delisle J, Barker B, Rank MA, Chia N, Schupp JM, Gillece JD, Cope EK. 2017. Mapping and comparing bacterial microbiota in the sinonasal cavity of healthy, allergic rhinitis, and chronic rhinosinusitis subjects. Int Forum Allergy Rhinol 7:561–569. https://doi.org/10.1002/air.21934.

70. Klinworth G, Pruesse E, Schweer T, Peoples J, Quad C, Horn M, Gloekner FO. 2013. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Res 41:e1. https://doi.org/10.1093/nar/gks808.

71. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JJ, Huttley GA, Kelley ST, Knight R, Lake J, Leffers P, Leiby B, Lax A, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. 2010. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7:335–336.

72. Edgar RC. 2010. Search and clustering orders of magnitude faster. Nat Biotechnol 28:469–471. https://doi.org/10.1038/nbt.1633.

73. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30:2114–2120. https://doi.org/10.1093/bioinformatics/btu170.

74. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, Huber T, Junier T, degnan P,半月石 R, et al. 2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25:2078–2079. https://doi.org/10.1093/bioinformatics/btp352.

75. Quinlan AR, Hall IM. 2010. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26:841–842. https://doi.org/10.1093/bioinformatics/btp033.

76. Freitas TA, Li PE, Scholz MB, Chain PS. 2015. Accurate read-based metagenome characterization using a hierarchical suite of unique signatures. Nucleic Acids Res 43:e69. https://doi.org/10.1093/nar/gkv180.

77. Segata N, Waldron L, Ballarini A, Narasimhan V, Jousson O, Huttenhower C. 2012. Metagenomic microbial community profiling using unique clade-specific marker genes. Nat Methods 9:811–814. https://doi.org/10.1038/nmeth.2066.

78. Bowers JR, Parise KL, Kelley EJ, Lemmer D, Schupp JM, Driebe EM, Engelthaler DM, Keim P, Barker BM. 2018. Direct detection of Coccidioides from Arizona soils using CoccienV, a highly sensitive and specific real-time PCR assay. Med Mycol https://doi.org/10.1093/mmy/mmy007.

79. Colman RE, Anderson J, Lemmer D, Lehmkuhl E, Georghiou SB, Heaton H, Wiggins K, Gillece JD, Schupp JM, Catanzaro DG, Crudu V, Cohen T, Rodwell TC, Engelthaler DM. 2016. Rapid drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates directly from clinical samples by use of amplicon sequencing: a proof-of-concept study. J Clin Microbiol 54:2058–2067. https://doi.org/10.1128/JCM.00553-16.

80. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30:2114–2120. https://doi.org/10.1093/bioinformatics/btu170.

81. Freitas TA, Li PE, Scholz MB, Chain PS. 2015. Accurate read-based metagenome characterization using a hierarchical suite of unique signatures. Nucleic Acids Res 43:e69. https://doi.org/10.1093/nar/gkv180.

82. Colman RE, Anderson J, Lemmer D, Lehmkuhl E, Georghiou SB, Heaton H, Wiggins K, Gillece JD, Schupp JM, Catanzaro DG, Crudu V, Cohen T, Rodwell TC, Engelthaler DM. 2016. Rapid drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates directly from clinical samples by use of amplicon sequencing: a proof-of-concept study. J Clin Microbiol 54:2058–2067. https://doi.org/10.1128/JCM.00553-16.

83. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30:2114–2120. https://doi.org/10.1093/bioinformatics/btu170.

84. Freitas TA, Li PE, Scholz MB, Chain PS. 2015. Accurate read-based metagenome characterization using a hierarchical suite of unique signatures. Nucleic Acids Res 43:e69. https://doi.org/10.1093/nar/gkv180.